Robert W. Baird Cuts iRhythm Technologies (NASDAQ:IRTC) Price Target to $200.00

iRhythm Technologies (NASDAQ:IRTC) had its price target trimmed by Robert W. Baird from $220.00 to $200.00 in a research report sent to investors on Friday,Benzinga reports. The brokerage currently has an outperform rating on the stock.

IRTC has been the subject of several other research reports. Freedom Capital upgraded shares of iRhythm Technologies to a “strong-buy” rating in a research note on Thursday, January 15th. Wells Fargo & Company upped their price target on iRhythm Technologies from $220.00 to $225.00 and gave the company an “overweight” rating in a research report on Tuesday, January 13th. The Goldman Sachs Group boosted their price objective on iRhythm Technologies from $180.00 to $202.00 and gave the company a “neutral” rating in a research note on Friday, October 31st. Citigroup increased their target price on shares of iRhythm Technologies from $205.00 to $242.00 and gave the stock a “buy” rating in a research report on Friday, October 31st. Finally, Canaccord Genuity Group boosted their price target on shares of iRhythm Technologies from $193.00 to $212.00 and gave the company a “buy” rating in a research report on Friday, October 31st. Two investment analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $211.62.

iRhythm Technologies Stock Performance

Shares of iRhythm Technologies stock opened at $150.96 on Friday. The firm has a market capitalization of $4.88 billion, a P/E ratio of -107.83 and a beta of 1.06. The company has a current ratio of 4.63, a quick ratio of 4.48 and a debt-to-equity ratio of 4.25. The business’s fifty day simple moving average is $164.65 and its 200 day simple moving average is $171.48. iRhythm Technologies has a 12 month low of $92.52 and a 12 month high of $212.00.

iRhythm Technologies (NASDAQ:IRTC) last released its earnings results on Thursday, February 19th. The company reported $0.29 EPS for the quarter, topping analysts’ consensus estimates of $0.02 by $0.27. The company had revenue of $208.89 million for the quarter, compared to analysts’ expectations of $202.61 million. iRhythm Technologies had a negative return on equity of 28.15% and a negative net margin of 5.96%.The business’s revenue for the quarter was up 27.1% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.04) EPS. As a group, analysts anticipate that iRhythm Technologies will post -1.98 EPS for the current year.

Insider Buying and Selling at iRhythm Technologies

In related news, insider Patrick Michael Murphy sold 2,478 shares of the business’s stock in a transaction dated Tuesday, December 2nd. The stock was sold at an average price of $184.83, for a total transaction of $458,008.74. Following the completion of the transaction, the insider directly owned 53,281 shares in the company, valued at $9,847,927.23. The trade was a 4.44% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Chad Patterson sold 280 shares of the company’s stock in a transaction dated Tuesday, December 2nd. The stock was sold at an average price of $184.83, for a total value of $51,752.40. Following the completion of the transaction, the insider owned 43,387 shares in the company, valued at $8,019,219.21. This represents a 0.64% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.68% of the stock is owned by company insiders.

Institutional Investors Weigh In On iRhythm Technologies

Institutional investors and hedge funds have recently bought and sold shares of the stock. Tudor Investment Corp ET AL bought a new stake in shares of iRhythm Technologies in the 3rd quarter worth approximately $3,439,800,000. RTW Investments LP bought a new stake in iRhythm Technologies in the fourth quarter worth $209,732,000. Millennium Management LLC grew its stake in shares of iRhythm Technologies by 197.4% during the fourth quarter. Millennium Management LLC now owns 826,376 shares of the company’s stock valued at $146,632,000 after buying an additional 548,519 shares during the last quarter. Arrowstreet Capital Limited Partnership increased its holdings in shares of iRhythm Technologies by 6,415.4% in the third quarter. Arrowstreet Capital Limited Partnership now owns 541,039 shares of the company’s stock worth $93,053,000 after buying an additional 532,735 shares during the period. Finally, Polar Capital Holdings Plc lifted its stake in shares of iRhythm Technologies by 24,782.1% in the 3rd quarter. Polar Capital Holdings Plc now owns 335,908 shares of the company’s stock valued at $57,773,000 after acquiring an additional 334,558 shares during the last quarter.

iRhythm Technologies News Summary

Here are the key news stories impacting iRhythm Technologies this week:

• Positive Sentiment: Q4 results beat estimates — Revenue $208.9M (+27.1% YoY) and EPS $0.29 topped consensus; management reported record quarterly revenue, improved gross margin and positive GAAP net income for the quarter. Globe Newswire: Q4 Results
• Positive Sentiment: Beating the street — Third‑party coverage highlights the earnings and revenue beat and improved profitability metrics (adjusted EBITDA, cash flow). These operational improvements support upside case over time. Zacks: Earnings Beat
• Neutral Sentiment: Company materials available — Earnings call transcript and slide deck published for investors to evaluate management commentary and forward drivers (AC C presentations and upcoming data cadence). Useful for confirming guidance/assumptions. Seeking Alpha: Call Transcript
• Neutral Sentiment: Market coverage noted positive market reaction after the print in some outlets — short-term sentiment can swing quickly as investors parse details. MassDevice: Market Reaction
• Negative Sentiment: Analysts trimmed price targets across several firms today (Canaccord, JPMorgan, Wells Fargo, Robert W. Baird) — ratings remain generally positive/overweight but lower targets reduce near‑term upside expectations and can pressure the stock. Benzinga: Analyst Target Changes
• Negative Sentiment: Insider selling and institutional rebalancing highlighted — multiple insider sales and large shifts in fund holdings raise concern about near-term selling pressure and supply overhang. Quiver: Insider & Institutional Activity

iRhythm Technologies Company Profile

iRhythm Technologies, Inc is a medical technology company that develops and commercializes wearable cardiac monitoring devices and associated data analytics services. Founded in 2006 and headquartered in San Francisco, California, the company’s flagship product is the Zio® patch, a discreet, single-use, continuous ECG recorder designed to monitor heart rhythms for up to 14 days. iRhythm’s digital diagnostics platform combines biosensor technology with proprietary algorithms to detect arrhythmias and streamline data interpretation for physicians.

The Zio service is prescribed by cardiologists and other healthcare providers to aid in the diagnosis of atrial fibrillation, bradycardia, tachycardia and other rhythm disorders.